A Breast cancer liquid biopsy employs non-solid biological tissue for sample and processing and is a crucial diagnostic technique for disorders like cancer. Liquid biopsy is preferable over surgical tissue biopsy since it is a noninvasive alternative approach that uses blood as a sample. Compared to a standard surgical biopsy, the method provides several benefits.
The breast cancer liquid biopsy market in 2021 was worth USD 124.46 million, and by 2030 it will be worth USD 604.71 million, growing at a 19.2% CAGR during the forecast period.
The significant factors driving the market’s growth include the patients’ and physicians’ increasing preferences for various noninvasive healthcare services, whether those services are treatments or diagnoses.
Market Dynamics
Drivers
- Increasing Incidence of Breast Cancer: Breast cancer is among the most prevalent type of cancer in women globally, and the incidence is increasing. The breast cancer liquid biopsy market is driven by the need for noninvasive and accurate diagnostic tests to detect breast cancer at an early stage.
- Advancements in Liquid Biopsy Technologies: The development of liquid biopsy technologies such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) has significantly improved the accuracy of diagnostic tests for breast cancer. As liquid biopsy technology advances, it is expected to become more accurate and cost-effective, driving the market growth.
- Cost-Effective and Noninvasive: Compared to traditional biopsy methods, liquid biopsy is a cost-effective and noninvasive diagnostic method, driving the demand for this technology. Patients prefer noninvasive methods, and healthcare providers are looking for cost-effective diagnostic solutions, making breast cancer liquid biopsy an attractive option.
- Increasing Demand for Personalized Medicine: With the increasing demand for personalized medicine, liquid biopsy is becoming an essential tool in cancer treatment. It provides information about the genetic makeup of the tumor, which can help healthcare providers select the most effective treatment options.
Restraints
The development of the market is severely constrained by the lack of accessibility to and knowledge of breast cancer in developing nations. Additionally, there is a shortage of qualified doctors, and late-stage diagnosis occurs sometimes.
Opportunity
More regulatory approvals from governmental organizations worldwide will probably aid the expansion of the breast cancer liquid biopsy market. Additionally, liquid biopsy is a clinically useful alternative to traditional methods for detecting breast cancer. According to a report, people with identifiable circulating tumor cells in their blood samples have a low risk of developing breast cancer again after receiving a liquid biopsy. All of these elements support several future chances for market expansion.
Market Segmentation
By Circulating Biomarker
In 2021, the circulating cell-free DNA (cfDNA) segment accounted for the biggest revenue share. It is due to the ability of cfDNA to diagnose recurrence or progression, detect developing genomic abnormalities linked to drug resistance, and track tumor molecular profiling in real-time at various time points.
During the forecast period, the circulating tumor cells (CTCs) segment will develop quickly. This is due to the capacity of CTCs to provide increased sensitivity as biomarkers for the early diagnosis of cancer, with larger CTCs counts being tied to a very high risk of getting cancer.
By Application
Due to the requirement for early treatment, the treatment selection category had the biggest revenue share in 2021. The importance of early detection, characterization, and management of breast cancer in its early stages has increased due to the development of liquid biopsies, making this clinical setting the most suitable to improve the likelihood of effective treatment selection and improved prognosis.
Regional Analysis
North America contributed for largest revenue share in 2021. This is due to rapid technical development, the use of liquid biopsies in treatment decision-making, and expanding government efforts. Due to higher expenditures and several biotechnology businesses producing the tests, the U.S. dominates the North American market.
Over the projection period, Asia Pacific will see profitable growth. The market is expanding because the population is expanding, there is a growing need for services, and more businesses are joining the market. With a sizable population comes a high incidence of cancer in the Asia Pacific. According to Global Cancer Statistics 2020, Asia was home to an estimated 58.3% of cancer deaths and about half of all cancer incidences in 2020.
Key Players
- Biocept Inc
- Qiagen
- F. Hoffmann-La Roche Ltd
- Johnson & Johnson (Janssen Diagnostics)
- Bio-Rad Laboratories
- Myriad Genetics
- Adaptive Biotechnologies
- Janssen Diagnostics
- Guardant Health Inc.
- Fluxion Biosciences Inc.
- Biodesix
- Epic Sciences
- Illumina Inc.
The breast cancer liquid biopsy market in 2021 was worth USD 124.46 million, and by 2030 it will be worth USD 604.71 million, growing at a 19.2% CAGR during the forecast period. The market is expanding due to the growing demand for noninvasive procedures, more knowledge of early detection and treatment, and an increase in the incidence of breast cancer.
Related Reports:
Endovascular Aneurysm Repair Market Report – The global endovascular aneurysm repair market will witness a robust CAGR of 5.8%, valued at $3.03 billion in 2021, expected to appreciate and reach $5.03 billion by 2030, confirms Strategic Market Research.